BioTime (NYSEAMERICAN:BTX) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07), Morningstar.com reports. The firm had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.74 million.
NYSEAMERICAN BTX opened at $1.55 on Friday. BioTime has a one year low of $0.66 and a one year high of $2.81.
A number of research firms have issued reports on BTX. Maxim Group reiterated a “buy” rating and issued a $3.00 price objective on shares of BioTime in a report on Wednesday, January 30th. Dawson James began coverage on BioTime in a report on Thursday, February 7th. They set a “buy” rating for the company. Zacks Investment Research upgraded BioTime from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a report on Thursday, January 3rd. Oppenheimer began coverage on BioTime in a report on Tuesday, December 11th. They set an “outperform” rating and a $3.50 price target for the company. Finally, HC Wainwright began coverage on BioTime in a report on Thursday, February 21st. They set a “buy” rating and a $4.00 price target for the company. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $3.05.
TRADEMARK VIOLATION NOTICE: “BioTime (BTX) Issues Earnings Results” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.com-unik.info/2019/03/15/biotime-btx-issues-earnings-results.html.
BioTime Company Profile
BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.
Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.